Partnership / Collaboration · Southeast Asia · Announced 27 Oct 2026
Institut Teknologi Bandung → Indofarma
State drugmaker Indofarma has signed an MoU with ITB, ITB spin-off EBM and a Danantara fund to turn Indonesian natural-material research into pharmaceutical raw materials, aiming to cut reliance on imported ingredients.
Parties: Institut Teknologi Bandung (ITB) (Indonesia) → Indofarma (Indonesia)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Indonesia (domestic and export markets)
- Therapeutic area
- Other
- Assets
- Natural-material pharmaceutical raw materials; Herbal medicines; MarkHerb marker compounds
- Announced
- 27 Oct 2026
Our analysis
Why this matters
On 27 October 2026 in Jakarta, Institut Teknologi Bandung (ITB), PT Danantara Development Management Fund (DDMF), state-owned drugmaker PT Indofarma (Persero) and ITB spin-off PT EBM Saintifik dan Teknologi signed a memorandum of understanding to turn research on Indonesian natural materials into national pharmaceutical raw materials. The stated aim is to reduce the domestic industry's dependence on imported active ingredients.
Indonesia imports most of its pharmaceutical raw materials, and successive governments have made ingredient self-sufficiency a policy goal. Bringing in a vehicle of Danantara, the sovereign investment agency, is the new element: it puts state capital alongside a university and a state manufacturer that needs a growth story. The focus on natural materials plays to Indonesia's biodiversity and its large traditional-medicine market.
The full analysis is free to read with a work email on this page.
Source: ANTARA News